Inhibitor development in non-severe haemophilia across Europe
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10316271" target="_blank" >RIV/00216208:11130/15:10316271 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064203:_____/15:10316271
Výsledek na webu
<a href="http://dx.doi.org/10.1160/TH14-12-1044" target="_blank" >http://dx.doi.org/10.1160/TH14-12-1044</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1160/TH14-12-1044" target="_blank" >10.1160/TH14-12-1044</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Inhibitor development in non-severe haemophilia across Europe
Popis výsledku v původním jazyce
Evidence about inhibitor formation in non-severe haemophilia and the potential role for clotting factor concentrate type is scant. It was the aim of this study to report inhibitor development in non-severe haemophilia patients enrolled in the European Haemophilia Safety Surveillance (EUHASS) study. Inhibitors are reported quarterly and total treated patients annually. Incidence rates and 95% confidence intervals (95% Cl) were calculated according to diagnosis and concentrate used. Between 1-10-2008 and31-12-2012, 68 centres reported on 7,969 patients with non-severe haemophilia A and 1,863 patients with non-severe haemophilia B. For haemophilia A, 37 inhibitors occurred in 8,622 treatment years, resulting in an inhibitor rate of 0.43/100 treatment years (95% Cl 0.30-0.59). Inhibitors occurred at a median age of 35 years, after a median of 38 exposure days (EDs; P25-P75: 20-80); with 72% occurring within the first 50 EDs. In haemophilia B, one inhibitor was detected in 2,149 treatment
Název v anglickém jazyce
Inhibitor development in non-severe haemophilia across Europe
Popis výsledku anglicky
Evidence about inhibitor formation in non-severe haemophilia and the potential role for clotting factor concentrate type is scant. It was the aim of this study to report inhibitor development in non-severe haemophilia patients enrolled in the European Haemophilia Safety Surveillance (EUHASS) study. Inhibitors are reported quarterly and total treated patients annually. Incidence rates and 95% confidence intervals (95% Cl) were calculated according to diagnosis and concentrate used. Between 1-10-2008 and31-12-2012, 68 centres reported on 7,969 patients with non-severe haemophilia A and 1,863 patients with non-severe haemophilia B. For haemophilia A, 37 inhibitors occurred in 8,622 treatment years, resulting in an inhibitor rate of 0.43/100 treatment years (95% Cl 0.30-0.59). Inhibitors occurred at a median age of 35 years, after a median of 38 exposure days (EDs; P25-P75: 20-80); with 72% occurring within the first 50 EDs. In haemophilia B, one inhibitor was detected in 2,149 treatment
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Thrombosis and Haemostasis
ISSN
0340-6245
e-ISSN
—
Svazek periodika
114
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
6
Strana od-do
670-675
Kód UT WoS článku
000362144300003
EID výsledku v databázi Scopus
2-s2.0-84943166338